Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

European Agency Recommends Approval of Sanofi’s Dengvaxia for Prevention of Dengue

By Catherine Sbeglia | October 22, 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorization for Sanofi’s tetravalent vaccine, Dengvaxia, for the prevention of dengue caused by dengue virus serotypes 1, 2, 3, and 4 in people who are between 9 and 45 years old, live in an endemic area, and already had a prior dengue virus infection. Approval of the vaccine, which would be the first for dengue virus cleared in the EU, is expected in December.

The most common mosquito-borne viral disease affecting people worldwide, dengue is seen primarily in tropical areas; tens of millions of cases occur each year resulting in approximately 20,000-25,000 deaths, mainly in children.1

Dengvaxia was evaluated in 31 clinical studies, conducted mostly in Latin America and the Asia Pacific. The trials included over 41,000 participants aged 9 months to 60 years receiving at least one dose of the vaccine. The data demonstrate that for people between 9 and 45 years of age, the vaccine has positive effects in preventing symptomatic and severe dengue disease in people who have had previous dengue infection and live in endemic areas. In people who have never had dengue, there is an increased risk of clinically severe dengue disease leading to hospitalization. Therefore, The CHMP recommends limiting the use of the vaccine to individuals with prior dengue virus infection, for whom laboratory confirmation of the previous infection is available before vaccination. 

The approved indication excludes the populations of the EU mainland and territories outside tropical areas since dengue is not endemic in these regions. However, a number of EU territories, mainly overseas, are situated in endemic areas, and these territories could benefit from this vaccine.

In December, authorities in the Philippines suggested that several children who had died after receiving Dengvaxia exhibited signs of “severe dengue.” However, Sanofi denied that there were any deaths related to its vaccine in the Philippines.

The CHMP opinion is a first step for Dengvaxia. The opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorization, and then decisions about price and reimbursement will be made. 

Reference

[1] https://ecdc.europa.eu/en/dengue-fever/facts/factsheet

(Source: The European Medicines Agency)

Related Articles Read More >

Johnson & Johnson
Feds halt J&J COVID-19 vaccine due to blood clot concern
pharmaceuticals
Analyzing FDA guidance on DDI studies for therapeutic proteins
mouse
When can computer models replace animal trials?
Intravacc
Intravacc touts preclinical, non-human results for COVID-19 nasal spray vaccine

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards